Bornert, O., Hogervorst, M., Nauroy, P., Bischof, J., Swildens, J., Athanasiou, I., . . . Nyström, A. (2021). QR-313, an antisense oligonucleotide, shows therapeutic efficacy for treatment of dominant and recessive dystrophic epidermolysis bullosa: A preclinical study. The journal of investigative dermatology, 141(4), . https://doi.org/10.1016/j.jid.2020.08.018
Chicago-Zitierstil (17. Ausg.)Bornert, Olivier, et al. "QR-313, an Antisense Oligonucleotide, Shows therapeutic Efficacy for Treatment Of dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study." The Journal of Investigative Dermatology 141, no. 4 (2021). https://doi.org/10.1016/j.jid.2020.08.018.
MLA-Zitierstil (9. Ausg.)Bornert, Olivier, et al. "QR-313, an Antisense Oligonucleotide, Shows therapeutic Efficacy for Treatment Of dominant and Recessive Dystrophic Epidermolysis Bullosa: A Preclinical Study." The Journal of Investigative Dermatology, vol. 141, no. 4, 2021, https://doi.org/10.1016/j.jid.2020.08.018.